Newer ROS1 inhibitors are in development, and investigational agents such as cabozantinib, entrectinib, repotrectinib, and DS-6051b have emerging results in early-phase clinical trials in ROS1-rearranged NSCLC (148–150). Here, ROS1 is linked to non-small cell lung carcinoma.